Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02195232 · ClinicalTrials.gov registry record · Phase 2

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

A Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer, sponsored by Jeffrey Zwicker, MD.

Completed
Registry status
Phase 2
Development phase
64
Enrollment target
11
Study locations

NCT02195232 is a Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer that has completed, run by Jeffrey Zwicker, MD. The registered enrollment target is 64 participants. The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02195232, a Phase 2 study of Thromboembolism of Vein VTE in Colorectal Cancer and Thromboembolism of Vein in Pancreatic Cancer, has completed, sponsored by Jeffrey Zwicker, MD.

COMPLETED
Registry status
Phase 2
Development phase
64 participants
Enrollment target
11
Study locations

Study Summary

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

Interventions

  • DRUG Isoquercetin

Study Locations (11)

Massachusetts

  • Boston VA Healthcare System - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Mount Auburn Hospital - Waltham

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • VA Northern California Health Care System - Sacramento

Connecticut

  • VA Connecticut Healthcare System - West Haven

District of Columbia

  • Veterans Affair Medical Center - Washington D.C.

Maine

  • York Hospital-Oncology Treatment Center - York Village

Missouri

  • Washington University in St. Louis - St Louis

Rhode Island

  • Providence VA Medical Center - Providence

Vermont

  • White River Junction VA Medical Center - White River Junction

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2015-01
Est. Completion 2019-10-22
Phase Phase 2

Sponsor

Jeffrey Zwicker, MD

1 total trials

What the Registry Record Tells You About NCT02195232

The ClinicalTrials.gov registry entry for NCT02195232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey Zwicker, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Thromboembolism of Vein VTE in Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isoquercetin is the first listed.

NCT02195232 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Massachusetts, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT02195232 about?

NCT02195232 is a clinical study titled "Cancer Associated Thrombosis and Isoquercetin (CATIQ)". This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

What is the current status of trial NCT02195232?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2015-01. Estimated completion is 2019-10-22.

What conditions does trial NCT02195232 study?

This clinical trial studies the following conditions: Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer.

What interventions are being tested in trial NCT02195232?

The interventions under investigation include: Isoquercetin (DRUG).

Who is sponsoring clinical trial NCT02195232?

This trial is sponsored by Jeffrey Zwicker, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02195232 being conducted?

This trial has 11 study locations across California, Connecticut, District of Columbia, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.